Key result
In patients with refractory dyspnea, no relationship was found between baseline dyspnea and response to 20 mg sustained release morphine (Spearman correlation 0.03, p = 0.88).
Why the study?
Does sustained release morphine improve dyspnea in patients with refractory dyspnea?
RCT (n=38)
crossover
Does sustained release morphine improve dyspnea in patients with refractory dyspnea?
Effect estimate: Spearman correlation 0.03
p-value: p=0.88
In patients with refractory dyspnea, baseline dyspnea severity does not predict response to sustained release morphine.
No takes yet. Share an insight, caveat, or question.
Baseline dyspnea severity does not predict morphine response; supports empiric opioid trials irrespective of initial intensity and challenges severity-stratified response assumptions.
Currow et al. (2007) conducted an RCT in refractory dyspnea (n=38). sustained release morphine vs. placebo was evaluated on Day 4 and day 8 morning and evening VAS scores (Spearman correlation 0.03, p=0.88). In patients with refractory dyspnea, no relationship was found between baseline dyspnea and response to 20 mg sustained release morphine (Spearman correlation 0.03, p = 0.88).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: